Gene Test Predicts Melanoma Metastases
By LabMedica International staff writers Posted on 07 Apr 2014 |
Image: A melanoma on a patient\'s skin (Photo courtesy of the US National Cancer Institute).
A gene expression profile (GEP) test can identify primary cutaneous melanoma tumors that are likely to metastasize in patients who had a negative sentinel lymph node biopsy.
The noninvasive 31-gene GEP test that is widely used to determine metastatic risk in Stage I and II melanoma patients has been compared to sentinel lymph node biopsy (SLNB) which has traditionally been the best prognostic test available for melanoma patients.
Scientists at Castle Biosciences Inc. (Friendswood, TX, USA) compared their test called DecisionDx-Melanoma to results from134 patients with Stage I, II, or III cutaneous melanoma. These 134 patients represented all patients in the initial clinical validation studies who had a documented sentinel lymph node procedure. The DecisionDx-Melanoma is a proprietary test carried out in the company’s laboratories.
In patients with a negative SLNB, a result interpreted as a lower risk for metastasis, the GEP test identified the vast majority of melanomas that ultimately progressed over the subsequent five year period. The rate of five year metastasis-free survival (MFS) was 55% for SLNB negative patients compared to 37% for SLNB positive patients The GEP test results showed improved prognostic accuracy in these same patients with an MFS of 87% for the low-risk (Class 1) patients and 31% for the high risk (Class 2) patients.
The GEP test showed improved prognostic accuracy, with an overall survival (OS) for GEP Class 1 patients of 92% compared to 49% for Class 2 patients. The GEP test was also analyzed in combination with SLNB status. The 20% of patients who had high risk results for both tests (GEP Class 2 and SLNB positive) had lower survival rates (MFS=34%; OS=53%). Similarly, the 31% of patients who had low risk results for both tests (GEP Class 1 and SLNB negative) had higher survival rates (MFS=82%; OS=92%). Importantly, in the 49% of patients who had results that were discordant, high risk outcome for one test, low risk for the other, the GEP test result correctly predicted the patients' clinical outcomes. Net reclassification improvement of GEP class over SLNB status was greater than 50%.
Pedram Gerami, MD, the study author and an associate professor of Dermatology at Northwestern University (Evanston, IL, USA), said, “The results from this study show the GEP test is an independent predictor of metastasis and death, and significantly improves upon sentinel lymph node biopsy for staging melanoma patients. Based upon this data, optimal use of the GEP test may be to identify high risk patients among those with a negative SLNB result, or for patients who are ineligible for or who decline a SLNB procedure.” The study was presented at the 72nd Annual Meeting of the American Academy of Dermatology held March 21-25 2104 in Denver, CO, USA).
Castle Biosciences Inc.
Northwestern University
Related Links:
The noninvasive 31-gene GEP test that is widely used to determine metastatic risk in Stage I and II melanoma patients has been compared to sentinel lymph node biopsy (SLNB) which has traditionally been the best prognostic test available for melanoma patients.
Scientists at Castle Biosciences Inc. (Friendswood, TX, USA) compared their test called DecisionDx-Melanoma to results from134 patients with Stage I, II, or III cutaneous melanoma. These 134 patients represented all patients in the initial clinical validation studies who had a documented sentinel lymph node procedure. The DecisionDx-Melanoma is a proprietary test carried out in the company’s laboratories.
In patients with a negative SLNB, a result interpreted as a lower risk for metastasis, the GEP test identified the vast majority of melanomas that ultimately progressed over the subsequent five year period. The rate of five year metastasis-free survival (MFS) was 55% for SLNB negative patients compared to 37% for SLNB positive patients The GEP test results showed improved prognostic accuracy in these same patients with an MFS of 87% for the low-risk (Class 1) patients and 31% for the high risk (Class 2) patients.
The GEP test showed improved prognostic accuracy, with an overall survival (OS) for GEP Class 1 patients of 92% compared to 49% for Class 2 patients. The GEP test was also analyzed in combination with SLNB status. The 20% of patients who had high risk results for both tests (GEP Class 2 and SLNB positive) had lower survival rates (MFS=34%; OS=53%). Similarly, the 31% of patients who had low risk results for both tests (GEP Class 1 and SLNB negative) had higher survival rates (MFS=82%; OS=92%). Importantly, in the 49% of patients who had results that were discordant, high risk outcome for one test, low risk for the other, the GEP test result correctly predicted the patients' clinical outcomes. Net reclassification improvement of GEP class over SLNB status was greater than 50%.
Pedram Gerami, MD, the study author and an associate professor of Dermatology at Northwestern University (Evanston, IL, USA), said, “The results from this study show the GEP test is an independent predictor of metastasis and death, and significantly improves upon sentinel lymph node biopsy for staging melanoma patients. Based upon this data, optimal use of the GEP test may be to identify high risk patients among those with a negative SLNB result, or for patients who are ineligible for or who decline a SLNB procedure.” The study was presented at the 72nd Annual Meeting of the American Academy of Dermatology held March 21-25 2104 in Denver, CO, USA).
Castle Biosciences Inc.
Northwestern University
Related Links:
Latest Molecular Diagnostics News
- Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods
- Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
- Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
- First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
- Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
- AI Technology-Based Blood Test Identifies Lung Cancer Earlier
- Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Months or Even Years before Relapse
- Prenatal Testing Offers Window for Finding Mother’s Cancer Risk
- New Molecular Test Detects More Cervical Cancer Cases
- New Panel Quickly and Accurately Identifies 16 Common Gastrointestinal Pathogens
- New DNA Testing Method Offers Faster and More Accurate Pathogen Identification
- Precise Cancer Detection Method as Quick and Easy as Blood Test
- DNA Spit Test More Accurate At Identifying Future Prostate Cancer Risk
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes